CipherBio Weekly Digest: Week of Jan 27 – Feb 2, 2022
This week’s funding events bring $1.77B in deals, $421M in Series A, 40 new companies added to CipherBio. Furthermore, lot of notable announcements in product clinical phases.
New Companies on CipherBio
Sign Up For Your Weekly Digest ➜
Top Deals Across Rounds
Septerna raises $100M in Series A round led by Third Rock Ventures. Also in Series A Enable Injections gets $215M led by Magnetar Capital. In Series B Athelas raises $132M led by General Catalyst. Patient 21 raises $142M in Series C round led by Target Global. Alto Pharmacy raises $200M in Series E led by Softbank Vision Fund. Maravai Life Sciences acquires MyChem for $240M. Akili Interactive Labs merger with a SPAC will net it up to $412M.
|Enable Injections||Series A||$215M|
|Patient 21||Series C||$142M|
|Alto Pharmacy||Series E||$200M|
|Maravai Life Sciences||Acquisition||$240M|
|Akili Interactive Labs||SPAC||$412M|
This Week’s Lead Investors in Top Rounds
Lead investors this week are Third Rock Ventures, Magnetar Capital, General Catalyst, GV, Target Global, Softbank Vision Fund.
Products and Clinical Phases
Viracta Therapeutics announces phase 1B/2 trial of Nana-Val in patients with advanced Epstein-Barr virus. Trevi Therapeutics completes enrollment in phase 2B/3 of Haduvio associated with chronic pruritus. Massachusetts-based Viridian Announces announces phase 1 trial of VRDN-002 for the treatment of thyroid eye disease. Arcutis starts their phase 3 trial of topical roflumilast foam in people with seborrheic dermatitis. Reviva Pharmaceuticals begins a phase 3 study of their product Brilaroxazine for the treatment of schizophrenia.
|Company||Product and Clinical Phase||Indications|
|Viracta Therapeutics||Nana-Val, Phase 1B/2||Epstein-Barr Virus, EBV Associated Lymphoma, Solid Tumors, Cancers and Other Neoplasms (NOS)|
|Viridian Announces||VRDN-002, Phase 1||Thyroid Eye Disease, Thyroid Disease, Eye Diseases|
|Aldeyra||Reproxalap, Phase 2||Dry Eye Diseases, Dry Eye|
|Trevi Therapeutics||Haduvio, Phase 2B/3||Pruritus, Peripheral Nervous System, Liver Disease|
|Arcutis Biotherapeutics||Roflumilast, Phase 3||Skin Disease, Seborrheic Dermatitis|
|Reviva||Brilaroxazine, Phase 3||Schizophrenia, Neurological Disorders, Psychiatric Disorders|
|Tracon Pharmaceuticals||TRC102, Phase 2||Lung Cancer, Mesothelioma|
|Aardvark Therapeutics||ARD 101, Phase 2||Metabolic Disorders, Inflammatory Disorders, Prader-Willi Syndrome|
40 Life Science Companies Added
This week we added 40 new life science companies.
|Volta Labs||Susterre Technologies||Yamo Pharmaceuticals|
|Kula Bio||Censys||Iasis Molecular Science|
To get all the latest life science deals and VC funding data delivered straight to your inbox weekly become a CipherBio PRO member.